论文部分内容阅读
目的通过检测血清SLPI及CA125水平,评估SLPI及其与CA125联合检测在卵巢癌诊断尤其早期诊断中的价值,以期提高卵巢癌的早期诊断率。方法研究对象:大连市妇产医院2006年7月-2007年12月期间收治的卵巢癌患者31例为卵巢癌组,按手术病理分期:Ⅰ-Ⅱ期13例,Ⅲ-Ⅳ期18例;同期住院的卵巢良性肿瘤患者24例为卵巢良性肿瘤组。同期在我院门诊体检的健康妇女及医院工作人员31例为健康对照组。所有患者均无炎症,末梢血白细胞数量<10×109/L,均无其他器官肿瘤病史,术前均未接受放疗、化疗及激素治疗。实验方法:血清SLPI检测采用ELISA法,血清CA125检测采用微粒子化学发光法。统计分析:应用SPSS11.5统计软件进行数据处理。两样本均数比较采用t检验,多样本均数比较采用方差分析。检验标准α=0.05。结果1.CA125的检测结果:(1)卵巢癌组血清CA125水平明显高于卵巢良性肿瘤组和对照组。(2)CA125水平与肿瘤分期有关,Ⅲ-Ⅳ期上皮性卵巢癌患者血清中CA125水平明显高于Ⅰ-Ⅱ期。(3)CA125对Ⅰ期卵巢癌诊断率低,仅55%。2.SLPI的检测结果:(1)卵巢癌组血清SLPI水平明显高于卵巢良性肿瘤组和对照组。(2)血清SLPI水平与卵巢癌患者的手术病理分期无关。(3)Ⅰ期卵巢癌患者血清中SLPI水平明显高于卵巢良性肿瘤组。(4)SLPI与CA125联合检测的灵敏度较单独检测高,但特异度降低。结论1.CA125对卵巢癌敏感,并随肿瘤期别的增加而升高,但早期诊断率低。2.卵巢癌患者的血清SLPI水平升高,但与肿瘤分期无关。3.SLPI于卵巢癌早期即升高,使之可能成为提高卵巢癌早期诊断率的一个有用的标志物。4.SLPI与CA125联合检测,可提高卵巢癌诊断的敏感度。
Objective To evaluate the value of combined detection of SLPI and CA125 in the diagnosis of ovarian cancer, particularly in the early diagnosis by detecting serum SLPI and CA125 levels in order to improve the early diagnosis rate of ovarian cancer. Methods Subjects: 31 patients with ovarian cancer who were treated in Dalian Maternity Hospital from July 2006 to December 2007 were ovarian cancer patients. According to the pathological staging, 13 cases were stage Ⅰ-Ⅱ and 18 cases were stage Ⅲ-Ⅳ. In the same period, 24 cases of benign ovarian tumor patients were benign ovarian tumor. The same period in our hospital outpatient examination of healthy women and hospital staff 31 cases of healthy control group. All patients had no inflammation, the number of peripheral blood leukocytes <10 × 109 / L, no other organ tumor history, preoperative radiotherapy, chemotherapy and hormone therapy. Experimental methods: Serum SLPI detection using ELISA, serum CA125 detection using particle chemiluminescence. Statistical Analysis: Application SPSS11.5 statistical software for data processing. The two samples were compared using t test, multiple sample mean comparison analysis of variance. Test standard α = 0.05. The results of 1.CA125 test results: (1) ovarian cancer serum CA125 levels were significantly higher than the benign ovarian tumor group and control group. (2) The level of CA125 was correlated with the tumor stage. The serum level of CA125 in patients with stage Ⅲ-Ⅳ epithelial ovarian cancer was significantly higher than that in stage Ⅰ-Ⅱ. (3) The diagnosis rate of CA125 for stage I ovarian cancer is low, only 55%. 2.SLPI test results: (1) serum ovarian cancer group SLPI levels were significantly higher than the benign ovarian tumor group and control group. (2) The level of serum SLPI has nothing to do with the surgical staging of ovarian cancer patients. (3) The serum level of SLPI in patients with stage I ovarian cancer was significantly higher than that in benign ovarian tumors. (4) The sensitivity of combined detection of SLPI and CA125 is higher than that of single detection, but the specificity is lower. Conclusion 1.CA125 is sensitive to ovarian cancer and increases with the tumor stage, but the early diagnosis rate is low. Ovarian cancer patients with elevated serum levels of SLPI, but has nothing to do with the staging of the tumor. 3.SLPI is elevated in the early stage of ovarian cancer, making it likely to become a useful marker to improve the early diagnosis of ovarian cancer. 4.SLPI and CA125 joint detection, can improve the sensitivity of ovarian cancer diagnosis.